ASCO Meeting 2022 Participation

**Friday, June 3**

*Oral Abstract Session*

Lung Cancer—Non-Small Cell Metastatic

*Overall Survival From A Phase II Randomized Study Of Ramucirumab Plus Pembrolizumab Versus Standard Of Care For Advanced Non–Small Cell Lung Cancer Previously Treated With Immunotherapy: Lung-MAP Nonmatched Substudy S1800A*

Author (Senior): Roy S. Herbst

Session: June 3; 2:00 – 5:00PM ET

Location: Hall D1 and live stream

*Case Based Panel*

Ethical Dilemmas among Genetic Testing

*Policy Implications for On-the-Ground Genetic Counseling*

Speaker: Amanda C. Ganzak

Session: June 3; 5:30 – 6:30PM ET

Location: S504 and on demand

**Saturday, June 4**

*Poster Session*

Gastrointestinal Cancer – Colorectal and Anal

*329 - Molecular characteristics of advanced colorectal cancer and multi-hit PIK3CA mutations*

Presenter: Michael Cecchini

Session: June 4; 9:00AM – 12:00PM ET

Location: Hall A and on demand

*Poster Session*

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

*207 – Treatment Patterns and Real-world Effectiveness of Rituximab Maintenance in Older Patients with Mantle cell Lymphoma: A Population-based analyses*

Presenter: Mengyang Di

Session: June 4; 9:00AM – 12:00PM ET

Location: Hall A and on demand

*Poster Session*

Genitourinary Cancer—Kidney and Bladder
**73 - Study EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients with muscle-invasive bladder cancer who are cisplatin-ineligible**
Presenter: Daniel P. Petrylak  
Session: June 4; 2:15 – 5:15PM ET  
Location: Hall A and on demand

**Poster Session**  
Gynecologic Cancer  
**472 - Biomarker associations of immune checkpoint inhibitor versus chemotherapy effectiveness in first-line metastatic endometrial carcinomas: A real-world study**  
Presenter: Alessandro Santin  
Session: June 4; 2:15 – 5:15PM ET  
Location: Hall A and on demand

**Poster Session**  
Professional Development and Education Advances  
**222 - Transdisciplinary research in energetics and cancer (TREC) training program for early career investigators**  
Presenter: Melinda L. Irwin  
Session: June 4; 2:15 – 5:15PM ET  
Location: Hall A and on demand

**Poster Session**  
Symptoms and Survivorship  
**307 - Evaluation of social connectedness, loneliness, and anxiety among cancer survivors during the 2020-2021 winter surge of COVID-19 pandemic**  
Presenter: Hermine Poghosyan  
Session: June 4; 2:15 – 5:15PM ET  
Location: Hall A and on demand

---

**Sunday, June 5**

**Oral Abstract Session**  
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary  
**4004 - A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: Final analysis of efficacy and evaluation of MGMT as a predictive biomarker (ECOG-ACRIN E2211)**  
Presenter: Pamela L. Kunz  
Session: June 5; 9:00AM – 12:00PM ET  
Location: Hall B1 and live stream

**Oral Abstract Session**  
Melanoma/Skin Cancers  
Chair & Panel Moderator: Harriet Kluger  
Session: June 5; 10:45AM – 1:45PM ET  
Location: S100a and live stream

**Education Session**  
Current Therapy for Metastatic Head and Neck Cancer: Evidence, Opportunities, and Challenges
**Education Session**

*High-Quality Survivorship Care: Best Practices and How to Make It Happen*

*Strategies for Effective Implementation of Survivorship Planning in Oncology Care*

Speaker & Panelist: Tara B. Sanft
Session: June 5; 9:00AM – 10:15AM ET
Location: E350 and on demand

**Education Session**

*Tailor-Ax: Personalizing the Treatment of Axilla in Patients With Early-Stage Breast Cancer*

*What Is the Optimal Axillary Management for Early-Stage, Clinical Node–Negative Disease?*

Chair: Rachel A. Greenup
Session: June 5; 5:30 – 6:45PM ET
Location: S100a and live stream

**Case-Based Panel**

*Less Is More: Practical De-Implementation Science Strategies to Improve Quality A Medical Oncology/Community Oncology Perspective*

Speaker & Panelist: Kerin B. Adelson
Session: June 5; 5:30 – 6:30PM ET
Location: E350 and on demand

**Plenary Session**

*Discussion of LBA3*

Discussant: Patricia LoRusso
Session: June 5; 2:00 – 4:40PM ET
Location: Hall B1 and on demand

**Poster Session**

*Central Nervous System Tumors*

**373 - Multicenter phase 2 trial of the PARP inhibitor (PARPi) olaparib in recurrent IDH1 and IDH2-mutant contrast-enhancing glioma**
Presenter: Kristina Fanucci
Session: June 5; 9:00AM – 12:00PM ET
Location: Hall A and on demand

---

**Monday, June 6**

**Oral Abstract Session**

*Gastrointestinal Cancer—Colorectal and Anal*
Chair & Panel Moderator: Michael Cecchini
Session: June 6; 10:45AM – 1:45PM ET
Location: Arie Crown Theater and live stream
Oral Abstract Session
Symptoms and Survivorship
Randomized trial of diet and exercise on chemotherapy completion in women with breast cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis (LEANer) study
Presenter: Tara B. Sanft
Session: June 6; 12:30 – 3:00PM ET
Location: E450 and live stream

Clinical Science Symposium
Looking Everywhere for Determinants of Benefit From Immunotherapy
Maximizing What We Learn from Slides
Discussant: Kurt A. Schalper
Session: June 6; 2:15 – 3:45PM ET
Location: Arie Crown Theater and live stream

Clinical Science Symposium
Including the Excluded: Advancing Care for All Patients With Lung Cancer
Panelist: Sarah Goldberg
Session: June 6; 5:30 – 7:00PM ET
Location: Hall A and on demand

Poster Session
Breast Cancer—Local/Regional/Adjuvant
365 - Prediction of pathologic complete response to neoadjuvant chemotherapy in breast cancer (SWOG S0800) using image analysis-based tumor infiltrating lymphocyte measurements
Presenter: Kim RM Blenman
Session: June 6; 9:00AM – 12:00PM ET
Location: Hall A and on demand

Poster Session
Breast Cancer – Metastatic
403 - The mutational profile of ER-, PR+, HER2- metastatic breast cancer
Presenter: Neal A. Fischbach
Session: June 6; 9:00AM – 12:00PM ET
Location: Hall A and on demand

Poster Session
Lung Cancer—Non-Small Cell Metastatic
72 - A first-in-human, phase 1 study of ASTX029, a dual-mechanism inhibitor of ERK1/2, in relapsed/refractory solid tumors
Presenter: Patricia LoRusso
Session: June 6; 9:00AM – 12:00PM ET
Location: Hall A and on demand

9037 – First Report of Safety/Tolerability and Preliminary Antitumor Activity of CAN-2049 in Inadequate Responders to Immune Checkpoint Inhibitors for Stage III/IV NSCLC
Author: Roy S. Herbst
### 9044 – Dynamic Changes in Serum Analyte Levels Associated with Clinical Outcome in Squamous Cell Lung Cancer Trial SWOG Lung-MAP S1400I of Nivolumab +/- Ipilimumab

Authors: Roy S. Herbst, Scott N. Gettinger

### 9046 – Multiomics Profiling and Association with Molecular and Immune Features in Association with Benefits from Immunotherapy for Patients with Previously Treated State IV or Recurrent Squamous Cell Lung Cancer from the Phase III SWOG LungMAP S1400I Trial

Authors: Roy S. Herbst, Scott N. Gettinger

### 9060 – A Phase II Study of Talazoparib plus Avelumab in Patients with Stage IV or Recurrent Nonsquamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (SWOG S1900C, Lung-MAP Sub-study NCT04173507)

Authors: Roy S. Herbst, Sarah B. Goldberg

Session: June 6; 9:00AM – 12:00PM ET
Location: Hall A and on demand

---

### Poster Session

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

### 64 – A Pilot Study of Ipilimumab and Nivolumab in Recurrent Extensive-stage Small Cell Lung Cancer after Platinum-based Chemotherapy

Presenter: Anne C. Chiang
Session: June 6; 9:00AM – 12:00PM ET
Location: Hall A and on demand

---

### Poster Session

Head and Neck Cancer

### 42 – Digital Spatial Profiling to Uncover Biomarkers of Immunotherapy Outcomes in Head and Neck Squamous Cell Carcinoma

Presenter: Niki Gavrielatou

Session: June 6; 2:15 – 5:15PM ET
Location: Hall A and on demand

---

### Poster Session

Health Services Research and Quality Improvement

### 6543 – Representativeness of Patients Enrolled in the Lung Cancer Master Protocol (Lung-MAP)

Author: Roy S. Herbst
Session: June 6; 2:15 – 5:15PM ET
Location: Hall A and on demand

---

### Poster Session

Melanoma/Skin Cancers

### 117 - Tumor mutational burden (TMB) in immune checkpoint inhibitor (ICI)-naïve and -experienced patients with metastatic melanoma treated with lifileucel, a tumor-infiltrating lymphocyte (TIL) cell therapy

Presenter: Harriett M. Kluger

Session: June 6; 9:00AM – 12:00PM ET
Location: Hall A and on demand

---

### Poster Session

Melanoma/Skin Cancers

### 148 - Clinical predictors of longer survival in patients with BRAFV600-mutated metastatic melanoma receiving immunotherapy prior to BRAF/MEK inhibition in the metastatic setting

Presenter: Harriett M. Kluger

Session: June 6; 9:00AM – 12:00PM ET
Location: Hall A and on demand
Presenter: Adriana Matutino Kahn  
Session: June 6; 2:15 – 5:15PM ET  
Location: Hall A and on demand

*Poster Discussion Session*  
Breast Cancer—Local/Regional/Adjuvant  
**Tailoring Therapy for HER2-Positive Breast Cancer**  
Discussant/Panelist: Ian E. Krop  
*Clinical outcomes and immune markers by race in a phase I/II clinical trial of durvalumab concomitant with neoadjuvant chemotherapy in early-stage TNBC*  
Presenter: Julia Foldi  
Session: June 6; 2:15 – 3:45PM ET  
Location: Hall BI and live stream

*Poster Discussion Session*  
Melanoma/Skin Cancers  
**What's Next? Treatment Choices After Anti-PD-1 Antibody**  
Discussant: Kelly Olino  
Session: June 6; 5:30 – 7:00PM ET  
Location: S100a and live stream

**Tuesday, June 7**

*Oral Abstract Session*  
Breast Cancer—Local/Regional/Adjuvant  
*Event-free survival by residual cancer burden after neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy for early TNBC: Exploratory analysis from KEYNOTE-522*  
Presenter/Panelist: Lajos Pusztai  
Session: June 7; 10:45AM – 1:45PM ET  
Location: Hall D1 and live stream